Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDURE: Peg Interferon Alfa-2b Maintenance in HIV-HCV Co-infection
NCT00381017Phase 3Withdrawn
- Sponsor
- Merck & Co.
- Start
- Sep 2006
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
01
Overview
Phase 3, randomised, open-label trial of peginterferon alfa-2b in hepatitis C (HCV) (2 arms), sponsored by Merck & Co. Primary endpoint: Time to any of the following clinical events: death, decompensation, liver transplant, hepatocellular carcinoma. Planned start Sep 2006; status: withdrawn.
02
Drugs
peginterferon alfa-2b
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00381017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00381017.